GFOR News and Press, Graf Acquisition Corp. IV

Graf Acquisition Corp. IV Announces Adjournment of Special Meeting to Approve Business Combination with NKGen Biotech, Inc. to September 25, 2023 PR Newswire THE WOODLANDS, Texas , Sept. 22, 2023 /PRNewswire/ -- Graf Acquisition Corp. IV (NYSE: GFOR, GFOR.U, GFOR...

2023-09-14 15:22:36 ET More on Graf Acquisition Corp. IV Financial information for Graf Acquisition Corp. IV For further details see: SPAC Graf IV delays NKGen merger vote as it seeks additional financing

Graf Acquisition Corp. IV Announces Adjournment of Special Meeting to Approve Business Combination with NKGen Biotech, Inc. to September 20, 2023 PR Newswire THE WOODLANDS, Texas , Sept. 14, 2023 /PRNewswire/ -- Graf Acquisition Corp. IV (NYSE: GFOR, GFOR.U, GFOR...

Graf Acquisition Corp. IV Announces Adjournment of Special Meeting to Approve Business Combination with NKGen Biotech, Inc. to September 13, 2023 PR Newswire THE WOODLANDS, Texas , Sept. 11, 2023 /PRNewswire/ -- Graf Acquisition Corp. IV (NYSE: GFOR, GFOR.U, GFOR...

THE WOODLANDS, Texas, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Graf Acquisition Corp. IV (NYSE: GFOR, GFOR-UN, GFOR-WT) (the “Company” or “Graf”), announced today that it intends to adjourn, without conducting any business, the special meeting of its stockholders to be held t...

SANTA ANA, Calif., Aug. 24, 2023 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic, and CAR-NK natural killer (“NK ...

Special Meeting of Graf Stockholders to Approve Proposed Business Combination to be Held on August 30, 2023 Post-Combination Company’s Securities to be Listed on Nasdaq Under Ticker Symbols “NKGN” and “NKGNW” THE WOODLANDS, Texas and SANTA ...

SANTA ANA, Calif. and THE WOODLANDS, Texas, July 06, 2023 (GLOBE NEWSWIRE) -- NKGen Biotech Inc. (“NKGen”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer (“NK”) cel...

Graf currently has proxies from more than 65% of its stockholders to approve an extension of the time it has to close the business combination with NKGen to September 29, 2023 (the “Extension”). Votes to approve the Extension will be cast at a special meeting of Graf stockholder...

2023-04-17 02:23:12 ET Clinical stage natural killer cell therapy company, NKGen Biotech enters merger with Graf Acquisition ( NYSE: GFOR ). NKGen is expected to have a pro forma enterprise value of at least $160M, based on $145M in pre-money equity value plus conversion to ...